The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Credit: Novo Nordisk. Self-paying patients will now be able to access NovoCare Pharmacy directly through the telehealth platform. The Company is working with Hims & Hers Health, Inc, LifeMD ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I ...

Hims & Hers (HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk (NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...